SCHEMBL3769783

SCHEMBL3769783

CCC1CCCCN1C(=O)c1ccc(N2CCN(CC(=O)N3CCN(C4CCC4)CC3)CC2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL3 Q96JM7 3/20 0.46
L3MBTL1 Q9Y468 3/20 0.46
GFER P55789 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
MBTD1 Q05BQ5 1/20 0.46
TP53BP1 Q12888 1/20 0.46
L3MBTL4 Q8NA19 1/20 0.46
MAPT P10636 4/20 0.45
LMNA P02545 3/20 0.45
KDM4E B2RXH2 2/20 0.45
ALDH1A1 P00352 3/20 0.45
HRH3 Q9Y5N1 6/20 0.43
HRH1 P35367 1/20 0.42
ITGB3 P05106 1/20 0.42
ITGA2B P08514 1/20 0.42
ALOX15 P16050 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
PARP1 P09874 1/20 0.41
HSD11B1 P28845 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3762971 0.89 L3MBTL1 (0.49) L3MBTL3L3MBTL1MAPTLMNAKDM4E
SCHEMBL3763113 0.89 GAA (0.53) L3MBTL3L3MBTL1GFERSMN1; SMN2MBTD1
SCHEMBL3773960 0.87 POLB (0.49) L3MBTL3L3MBTL1GFERSMN1; SMN2MBTD1
SCHEMBL3767835 0.87 POLB (0.49) L3MBTL3L3MBTL1GFERSMN1; SMN2MBTD1
SCHEMBL3771076 0.87 HRH3 (0.47) L3MBTL3L3MBTL1MAPTLMNAKDM4E
SCHEMBL3771754 0.85 GAA (0.48) L3MBTL3L3MBTL1GFERSMN1; SMN2MBTD1
SCHEMBL3771828 0.85 L3MBTL3 (0.60) L3MBTL3L3MBTL1GFERSMN1; SMN2MBTD1
SCHEMBL3767563 0.84 L3MBTL3 (0.59) L3MBTL3L3MBTL1GFERSMN1; SMN2MBTD1
SCHEMBL13005932 0.84 L3MBTL3 (0.59) L3MBTL3L3MBTL1GFERSMN1; SMN2MBTD1
SCHEMBL3769793 0.82 ALDH1A1 (0.51) GFERSMN1; SMN2MAPTLMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 L3MBTL3 1357/4885L3MBTL1 1468/4885GFER 3130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.